The Utility of Biofire Filmarray in Evaluation of Entero Pathogens Triggers in Patients With Chronic Diarrhea
NCT04269174 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2020-02-17
Summary
Chronic diarrhea is a common condition and a key symptom in many disorders. It is a major cause of morbidity and mortality worldwide and one of the most common reasons for referral to a gastroenterology clinic.The prevalence varies depending on population and the definition of diarrhea used. It affects approximately 5% of the population at any given point in time, although the exact prevalence is unknown. Diarrhea is associated with 4 pathophysiological mechanisms: osmotic, secretory, exudative and altered motility. It is more useful to classify patients presenting with symptoms of diarrhea according to ''functional'' or ''organic'' characteristics. It is usually difficult to make a reliable differentiation between organic and functional causes in patients with chronic diarrhea based only on history and physical examination .
The standard evaluation of patients with chronic diarrhea that begins with a detailed history, a careful physical examination and then basic diagnostic tests is critical for optimal treatment and prevention. Initially, thought needs to exclude several other possibilities as (a) fecal incontinence masquerading as diarrhea, (b) iatrogenic diarrhea due to drugs, surgery, or therapeutic radiation, (c) chronic infections, and (d) irritable bowel syndrome with diarrhea (IBS-D).
The detection of a broad array of potentially offending agents has traditionally required a combination of microbiologic approaches, including bacterial culture, antigen detection, microscopy, and polymerase chain reaction (PCR). The new multiplex PCR-based panels have several advantages over conventional methods including (i) reduced sample volume requirements, (ii) broad coverage without the need to select specific tests, (iii) enhanced ability to detect coinfections (iv) increased sensitivity and specificity as high as 97-100% and (v) higher throughput.The food and drug administration (FDA) cleared and recommended the use of FilmArray GI panel (BioFire Diagnostics), which targets 22 analytes (bacteria with bacterial toxin, viruses, and parasites)
Conditions
- Chronic Diarrhoea
- Antibiotic Resistant Strain
- Polymerase Chain Reaction
Sponsors & Collaborators
-
Shaimaa Mahmoud Abd El-mouez
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-29
- Primary Completion
- 2020-12-31
- Completion
- 2021-01-31
More Related Trials
-
Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
NCT03278912 ·Status: WITHDRAWN
-
The Gut Virome as a Trigger for IBD: From Metagenomics to Pathogenesis
NCT05906680 ·Status: UNKNOWN
-
Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients
NCT05720221 ·Status: COMPLETED
-
Microbial and Human Determinants of the Onset of IBD Flares
NCT05463900 ·Status: ACTIVE_NOT_RECRUITING
-
Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
NCT03841045 ·Status: UNKNOWN
-
Human and Microbial Determinants of the Onset of IBD Flares
NCT06967311 ·Status: RECRUITING
-
Endocytoscopy for in Vivo Determination of Mucosal Inflammatory Cells and Intestinal Disease Activity in Inflammatory Bowel Disease (IBD)
NCT01289366 ·Status: COMPLETED
-
Composite Ratios Boost CRP's Power in Monitoring Ulcerative Colitis.
NCT07261579 ·Status: COMPLETED
-
Response Assessment in SB CD
NCT03646708 ·Status: ACTIVE_NOT_RECRUITING
-
A Diagnostic Accuracy Study Testing Fecal Biomarkers In Comparison To Endoscopic Examination
NCT04849936 ·Status: UNKNOWN
-
Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis
NCT05653791 ·Status: UNKNOWN
-
Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers
NCT02309827 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis
NCT01453491 ·Status: COMPLETED ·Phase: PHASE1
-
The Inflammatory Bowel Disease - Anti-Inflammatory Diet (IBD-AID)
NCT04757181 ·Status: COMPLETED ·Phase: NA
-
Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis
NCT05333471 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease
NCT05986136 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
NCT05181137 ·Status: UNKNOWN ·Phase: PHASE3
-
Cytokines and Genes in Therapeutic Response in Crohn's Disease
NCT03266471 ·Status: COMPLETED
-
Delayed Diagnostic Time& Inflammatory Bowel Diseased Patients
NCT04952558 ·Status: UNKNOWN
-
Defining Predictors of RT Response to Vedolizumab in IBD
NCT03142321 ·Status: COMPLETED ·Phase: PHASE4
-
Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
NCT00972088 ·Status: COMPLETED ·Phase: NA
-
Genome Analysis Across Populations in Inflammatory Bowel Disease
NCT06042387 ·Status: RECRUITING
-
Gene Expression in Inflammatory Bowel Disease
NCT01171872 ·Status: ENROLLING_BY_INVITATION
-
Biomarker-based Multidisciplinary Team (Bio-MDT) Approach to Personalized Microbial-targeted Treatment of Pouchitis and Crohn's Disease
NCT04082559 ·Status: UNKNOWN ·Phase: NA
-
Manipulating the Microbiome in IBD by Antibiotics and FMT
NCT02033408 ·Status: COMPLETED ·Phase: NA